Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Onkologie|July 7, 2001
Combination of Bolus 5-Fluorouracil, Folinic Acid and Mitomycin C in Advanced Gastric Cancer: Results of a Phase II TrialG. Hartung, R. Hofheinz, D. Buchheidt, et al.
Cancer Treatment Reports|April 1, 1986
Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancerG Schnitzler, W Queisser, M E Heim, et al.
Klinische Wochenschrift|February 15, 1984
Combination chemotherapy (VAC/FMC) with immunostimulation in metastatic breast cancer: a randomized study comparing different times and routes of administration of Corynebacterium parvumD Fritze, B Massner, R Becher, et al.
Onkologie|April 1, 1987
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)"H Flechtner, W Queisser, M E Heim, et al.
Deutsche Medizinische Wochenschrift (1946)|December 7, 1979
[Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)]A C Mayr, H J Senn, W M Gallmeier, et al.
American Journal of Surgery|November 1, 1976
Immunotherapy of cancer with "immune" RNA. A preliminary reportY H Pilch, J B de Kernion, D G Skinner, et al.
Onkologie|November 6, 2001
Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancerG Hartung, R D Hofheinz, A Wein, et al.
Klinische Wochenschrift|June 15, 1982
A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancerD Fritze, R Becher, B Massner, et al.
International Journal of Systematic and Evolutionary Microbiology|July 2, 2009
Proposed minimal standards for describing new taxa of aerobic, endospore-forming bacteriaN A Logan, O Berge, A H Bishop, et al.
Anti-Cancer Drugs|August 13, 2005
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBCG von Minckwitz, I Chernozemsky, L Sirakova, et al.
Pageof 6